Epcoritamab Plus R-CHOP Cuts Lymphoma Progression Risk by 51% in Landmark Phase 3 Trial
AbbVie and Genmab report Phase 3 Epcore DLBCL-2 results: epcoritamab (Epkinly) added to R-CHOP reduces lymphoma progression or death by 51% (HR 0.49) in newly diagnosed DLBCL. Polivy rival targets…